Abstract
The peroxisome proliferator-activated receptors (PPARs) are a primary regulator of lipid metabolism. Potency for activation of PPARγ, one of a subfamily of PPARs, particularly mirrors glucose lowering activity. We prepared thiazolidinediones featuring benzoxazole moiety for subtype selective PPARγ activators. 5-[4-[2-(Benzoxazol-2-yl-alkylamino)ethoxy]benzyl]thiazo-lidine-2, 4-diones have been prepared by Mitsunobu reaction of benzoxazolylalkylaminoethanol8 and hydroxybenzylthiazolidinedione6 and their activities were evaluated. Most compounds tested were identified as potent PPARγ agonists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 23, 1605–1611 (2000).
Berger, J. and Moller, D. E., The mechanisms of action of PPARs.Ann. Rev. Med., 53, 409–435 (2002).
Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Snith, S. A., and Thurlby P. L., [[Omega-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.J. Med. Chem., 37, 3977–3985 (1994).
Dahl-Jorgensen, K. and Brinchmann-Hansen, O., Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study.Br. Med. J., 293, 1195–1199 (1986).
Defronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview.Diabetes Care, 15, 318–368 (1992).
Defronzo, R. A., Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.Diabetes, 37, 667–687 (1988).
Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism.Endcrine Rev., 20, 649–688 (1999).
Feldt-Rasmussen, B., Mathisesn, E., and Deckert, T., Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes.Lancet, 2, 1300–1304 (1986).
Holman, R. R. and Turner, R. C.,Textbook of Diabetes; Pickup, J. C., Williams, G. Eds.; Blackwell Scientofic Publications: London, pp 462–476 (1991).
Ibrahimi, A., Teboul, L., Gaillard, D., Amir, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimardi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.Mol. Pharmacol., 46, 1070–1076 (1994).
Kersten, S., Desvergne, B., and Wahli, W., Roles of PPARs in health and disease.Nature, 405, 421–424 (2000).
Kletzien, R. F., Clark, S. D., and Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent.Mol. Pharmacol., 41, 393–398 (1992).
Lehmann, J. M., Moorre, L. B., Smith-Oliver, T. A., Wilkinson, W. O., Wilson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).J. Biol. Chem., 270, 12953–12956 (1995).
Martin, G., Schoonjans, K., Staels, B., and Aurex, J., PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes.Atheroscrelosis, 137 (Suppl), S75-S80 (1998).
Morita, H., Mori, H., and Kobayashi, Y., Process for the production of a thiazolidine derivative. GB 2324089A (1998). Ruderman, N. B. and Scheneider, S. H., Diabetes, exercise, and atherosclerosis.Diabetes Care, 15 (Suppl. 4), 1787–1793 (1992).
Sohda, T., Momose, Y, Meguro, K., Kawamatsu, Y., Sugiyama, Y, and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4- thiazolidinediones.Arzneim.-Forsch., 40, 37–42 (1990).
Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y, Kurumada, T., Hasegawa, K., and Horikoshi, H., Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.J. Med. Chem., 32, 421–428 (1989).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jeon, R., Park, S. Synthesis and biological activity of Benzoxazole containing thiazolidinedione derivatives. Arch Pharm Res 27, 1099–1105 (2004). https://doi.org/10.1007/BF02975111
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02975111